The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia

BJU International

Volumn 94, Issue 3, 2004, Pages 338-344

  Gerber, Glenn S ^a   Fitzpatrick, John M ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

BPH; Extract; IPSS; LUTS; Outcome; Phytotherapy; Serenoa repens; Trials; Urinary flow rate

Indexed keywords

ALFUZOSIN; DUTASTERIDE; FINASTERIDE; LIPOXYGENASE; PHOSPHOLIPASE A2; PRAZOSIN; SABAL EXTRACT; TAMSULOSIN; TERAZOSIN;

CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSURIA; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; IMPOTENCE; LIBIDO DISORDER; LONG TERM CARE; META ANALYSIS; MICTURITION; MICTURITION DISORDER; NOCTURIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROGRADE EJACULATION; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; SABAL; SCORING SYSTEM; SEXUAL DYSFUNCTION; URETHRA DISEASE; URINARY FREQUENCY; URINARY TRACT OBSTRUCTION; URINARY URGENCY; URINE FLOW RATE;

ALGORITHMS; ANDROGEN ANTAGONISTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; META-ANALYSIS; PATIENT COMPLIANCE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SERENOA; URINARY RETENTION; URINATION;

EID: 4344601194     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04962.x     Document Type: Review

References (53)

1. Walsh PC. Benign prostatic hyperplasia. In Walsh PC, Retik AB, Vaughn ED, Wein AJ eds. Campbell's Urology, 6th edn. Philadelphia: WB Saunders, 1992: 1007-27
2. Gerber GS. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep 2002; 3: 285-91
3. Vallancien G, Pariente P. Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France. Prostate Cancer Prostatic Dis 2001; 4: 124-31
4. McConnell JD, Barry MJ, Bruskewitz RC et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guideline number 8. AHCPR Publication no. 94-0582. Agency for Health Care Policy and Research. Rockville, MD: Public Service US Department of Health and Health Sciences, 1994
5. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997; 31: 272-80
6. Frankel SJ, Donovan JL, Peters TI et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51: 677-85
7. Richard F, Lukacs B, Jardin A et al. Results of an epidemiologic surgery carried out with men 50-80 years of age to study urinary disorders, quality of life and sexual function. Prog Urol 2001; 11: 250-63
8. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol 1999; 36: 609-20
9. Chapple CR, Baert L, Thind P, Hofner K, Hoe GS, Spangberg A. Tamsulosin 0.4 mg once daily. Ttolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 1997; 32: 462-70
10. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185-91
11. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41
12. 5th International Consulations of BPH. Recommendations of the International Scientific Committee. Paris: 2000
13. Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P. Effect of the lipido-sterolic extract of Serenoa repens (Permixon®) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998; 33: 340-7
14. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon®). A 5α-reductase types I and II inhibitor - new evidence in a coculture model of BPH. The Prostate 1999; 40: 232-41
15. Carilla E, Briley M, Fauran F et al. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 1984; 20: 521-3
16. Di Silverio F, Monti S, Sciarra A et al. Effects of long-term treatment with Serenoa repens (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. The Prostate 1998; 37: 77-83
17. Vela Navarette R, Garcia Cardoso J, Bara A, Manzabeita F, Lopez Farre A. Effects of the lipido sterolic extract of Serenoa repens (Permixon) on infiltrating cells and inflammatory markers in prostatic tissues from BPH patients. Eur Urol 2002; 1 (Suppl. 1): 62
18. Paubert-Braquet M, Mencia-Huerta JM, Gousse H, Braquet P. Effect of the lipidic lipido-sterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins, Leukotrienes Essential Fatty Acids 1997; 57: 299-304
19. Ragab A, Ragab-Thomas JMF. Delhon A et al. Effects of Permixon® (Sereprostat® in Spain) on phospholipase A2 activity and on arachidonic acid metabolism in cultured prostatic cells. In Di Silverio F, Steg A eds. New Trends in Bladder Cancer Chemotherapy - New Trends in BPH Aetiopathogenesis. Proceedings of the International Workshop in Urology 1987 July 22-25. Cannes: Rome: Acta Medica 1988: 293-6
20. Marks LS, Partin AP, Epstein JI et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000; 163: 1451-6
21. Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol 2000; 164: 876-81
22. Vacherot F, Azzouzn M, Gil-Diez-de-Medina S et al. Effect of Permixon on apoptosis and proliferation in the prostate of patients with BPH. J Urol 1999; 161: 362A
23. Pytel YA, Lopatkin N, Gorilovsky L, Vinarov A, Sivkov A, Raynaud JP. Long-term clinical and biological effects of the lipido-sterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther 2002; 19: 297-306
24. Aliaev G, Vinarov AZ, Lokshin KL, Spivak LG. Five-year experience in treating patients with prostatic hyperplasia patients with permixone (Serenoa repens 'Pierre Fabre Medicament) [in Russian]. Urologiia 2002; 1: 23-5
25. Stepanov VN, Siniakova LA, Sarrazin B, Raynaud JP. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon®) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. Advanc Ther 1999; 16: 231-41
26. Mandressi A, Montanari E, Trinchieri A et al. Treatment of uncomplicated benign prostatic hyperplasia (BPH by an extract of Serenoa repens: clinical results. J Endocrinol Invest 1987; 10 (Suppl. 2):
27. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984; 18: 461-2
28. Cukier J, Ducassou J, Le Guillou M et al. Serenoa repens extract vs placebo. C R Ther Pharmacol Clin 1985; 4: 15-21
29. Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995; 9: 291-7
30. Carraro JC, Raynaud JP, Koch G et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1,098 patients. The Prostate 1996; 29: 231-40
31. Debruyne F, Koch G, Boyle P et al. Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002; 41: 497-507
32. Grasso M, Montesano A, Buonaguidi A et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Españoles Urología 1995; 48: 97-103
33. Hruby S, Djavan B, Reissigl A et al. Progression delay in men with mild symptoms of bladder outlet obstruction: a prospective comparative study of phytotherapy, watchful waiting and placebo. J Urol 2003; 169: 332A
34. Authie D, Cauquil J. Appreciation de l'efficacite de Permixon® en pratique quotidienne. C R Ther Pharmacol Clin 1987; 56: 4-13
35. Foroutan F. Wirksamkeit und Vertraglichkeit von Permixon® bei einem grosseren Patientenkollektiv (592 Patienten) unter Praxisbedingungen. J Urol Urogynakol 1997; 2: 17-21
36. Emili E, Lo Cingo M, Petrone U. Risulti clinici su un nueovo farmaco nella terapia dell-ipertrofia della prostate (Permixon®). Urologia 1983; 50: 1042-9
37. Tasca A, Barulli M, Cawazzana A et al. Treatment of obstruction in prostatic adenoma using extra et of Serenoa repens. Double blind clinical test v. placebo. Minerva Urol Nefrol 1985; 37: 87-91
38. Boccafoschi C, Annoscia S. Comparison of Serenoa repens extract and placebo in controlled clinical trial in patients with prostatic adenomatosis. Urologia 1983; 50: 1-14
39. Reece SH, Memon A, Smart CJ et al. The value of Permixon in benign prostatic hypertrophy. Br J Urol 1986; 58: 36-40
40. Adriazola Semino M, Lozano OJ, Garcia CE et al. Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and Serenoa repens. Arch Esp Urol 1992; 45: 211-3
41. Lopatkine N, Gorilovsky L, Vinarov A, Fiet J, Raynaud JP. Long term clinical and biological effects of a lipido-sterolic extract of Serenoa repens (Permixon) in patients with symptomatic BPH. Proceedings of the 5th International Consultation on BPH. Paris, June 25-28, 2000
42. Plosker GL, Brogden RN. Serenoa repens (Permixon®). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996; 9: 379-95
43. Lieber MM. Pharmacologic therapy for prostatism. Mayo Clin Proc 1998; 73: 590-6
44. 14C]-beta-sitosterol. Eur J Drug Metab Pharmacokinet 1997; 22: 73-83
45. Rosen RC, O'Leary M, Altwein JE et al. LUTS and male sexual dysfunction: the multi-national survey of the ageing male. J Urol 2002; 167: LB04
46. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55: 533-9
47. Boyle P, Robertson C, Lowe F, Roehrborn CG. Meta-analysis of Permixon in treatment of symptomatic benign prostatic hyperplasia: an update. J Urol 2003; 169 (Suppl. 4): 1297
48. Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001; 58: 717-22
49. Boyle P, Gould L, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
50. Habib FK, Ross M, Lyons V, Chapman K. Permixon inhibits the 5α reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer. In press
51. Roehrborn CG. BPH experts examine current trends, future directions. Urol Times 2000; 28: 33-4
52. Feifer AH, Fleshner NE, Klotz L. Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol 2002; 168: 150-4
53. Raynaud JP, Cousse H, Martin JM. Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of Permixon®. J Steroid Biochem Mol Biol 2002; 82: 233-9